---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-013308"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2021-10-20T23:59:59+00:00"
generated_at: "2026-06-28T19:43:13.736960+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics appoints Matthias Alder as COO effective Oct 15, 2021

## Summary
- Annual base salary of $400,000; eligible for 35% incentive target under management plan.
- Receives option grant of 200,000 shares with standard vesting and 200,000 RSUs tied to business/clinical milestones.
- Alder joins from Autolus Therapeutics where he was Chief Business Officer; previously EVP at Sucampo Pharmaceuticals.
- Appointment supports preparation for lead program in Gaucher and Parkinson's to enter clinical trials in 2022.

## SEC filing metadata
- accession: 0001558370-21-013308
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2021-10-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837021013308/0001558370-21-013308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837021013308/ganx-20211015x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-013308
- JSON: https://secwatch.observer/filing/0001558370-21-013308.json
- Plain text: https://secwatch.observer/filing/0001558370-21-013308.txt

## Key facts
- Executive change
  Matthias Alder was appointed as Chief Operating Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On October 19, 2021, Gain Therapeutics, Inc. (the “Company”) publicly announced the appointment of Matthias Alder, age 56, to serve as the Company’s Chief Operating Officer effective as of October 15, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837021013308/0001558370-21-013308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.